ALEMBIC-BOSENTAN TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
13-12-2021
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
BOSENTAN (BOSENTAN MONOHYDRATE)
Beschikbaar vanaf:
ALEMBIC PHARMACEUTICALS LIMITED
ATC-code:
C02KX01
INN (Algemene Internationale Benaming):
BOSENTAN
Dosering:
62.5MG
farmaceutische vorm:
TABLET
Samenstelling:
BOSENTAN (BOSENTAN MONOHYDRATE) 62.5MG
Toedieningsweg:
ORAL
Eenheden in pakket:
10/30/60/1000
Prescription-type:
Prescription
Therapeutisch gebied:
VASODILATING AGENTS
Product samenvatting:
Active ingredient group (AIG) number: 0145922001; AHFS:
Autorisatie-status:
APPROVED
Autorisatie datum:
2021-12-16
Productkenmerken
______________________________________________________________________________
Alembic-Bosentan Page 1 of 42
PRODUCT MONOGRAPH
PR
ALEMBIC-BOSENTAN
Bosentan Tablets
62.5 mg and 125 mg Bosentan (as Bosentan Monohydrate)
Endothelin Receptor Antagonist
DATE OF REVISION:
December 13, 2021
MANUFACTURED BY:
Alembic Pharmaceuticals Limited
Alembic Road
Vadodara
–
390003
Gujarat, India
CANADIAN IMPORTER AND DISTRIBUTOR:
Alembic Pharmaceuticals Canada Ltd.
225
Gibraltar Road, Unit 5
Vaughn, Ontario
L4H 4P9
Control #
258718
______________________________________________________________________________
Alembic-Bosentan Page 2 of 42
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL USE
..............................................................................
3
CONTRAINDICATIONS
...................................................................................................
3
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
...................................................................................................
8
DRUG INTERACTIONS
..................................................................................................
17
DOSAGE AND ADMINISTRATION
..............................................................................
20
OVERDOSAGE
................................................................................................................
21
ACTION AND CLINICAL PHARMACOLOGY
............................................................ 22
STORAGE AND
STABILITY..........................................................................................
24
SPECIAL HANDLING INSTRUCTIONS
.......................................................................
24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................
Lees het volledige document
